Oppenheimer upgraded Compass Pathways (CMPS) to Outperform from Perform with a $15 price target The firm is citing it higher conviction that the company’s COMP360 will “lead the revolution of psychedelic medicine” for neuropsychiatry, the analyst tells investors in a research note. COMP360, or psilocybin, should become the first ever FDA-approved classical psychedelic therapy for treatment-resistant depression patients, where the firm sees a $1.5B peak sales opportunity, the firm added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways upgraded to Outperform from Perform at Oppenheimer
- Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector
- Psychedelic: Compass Pathways, GH Research report Q3 earnings
- Compass Pathways Accelerates Launch Plans Amid Positive FDA Talks
- Compass Pathways Earnings Call Highlights Progress and Plans